/
Other
Phase IB
20
Pipeline Programs↗
7
Active Trials↗
19
Companies Involved↗
Phase IB is an emerging landscape with 20 programs across 19 companies. The most active players are Forward Pharmaceuticals Co., Ltd., Ascentage Pharma Group Inc., Shanghai Hengrui Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 19
Phase 211
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
95%
Small molecule
18 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
20
clinical trials
Completed9 · 45%
Recruiting4 · 20%
Terminated2 · 10%
Not yet recruiting2 · 10%
Unknown status1 · 5%
Withdrawn1 · 5%
Other1 · 5%
Clinical Trials
Trial Activity
20 trials
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05953350·29 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)